In addition to being licensed for the treatment of acute attacks, Cinryze is also licensed for pre-procedure prevention and for routine prevention when oral prevention or repeat acute treatment is inadequate or not tolerated.
Clinical studies
In an open-label study involving 91 procedures (medical, dental or surgical) in 41 patients (8 children and 33 adults), 98% of patients who received a single dose of the C1-esterase inhibitor did not have an acute attack of angioedema within 72 hours.1
The C1-esterase inhibitor demonstrated efficacy in routine prevention in a double-blind, placebo-controlled crossover study in 22 patients over a 24-week period. The number of attacks per 12-week period was reduced by half in patients who received prophylactic C1-esterase inhibitor compared with those who received placebo (6.26 vs 12.73, p<0.0001).2
Cinryze is licensed only for use in adults and adolescents and not in children.
Other treatment options
Current options for the treatment of acute attacks of angioedema include another human-plasma-derived C1-esterase inhibitor product (Berinert) and a C1-esterase inhibitor analogue produced from transgenic rabbits, conestat alfa (Ruconest); however, neither product is licensed for pre-procedure or routine prevention.
References:
- Zuraw BL, et al. N Engl J Med 2010; 363: 513–22.
- Lumry W et al. Poster presented at American Academy of Allergy Asthma & Immunology Annual Meeting, San Francisco, USA, March 2011: P903.
View Cinryze drug record
Further information: ViroPharma Ltd
